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http://dx.doi.org/10.1016/j.jds.2013.0Abstract Background/purpose: Bisphosphonate-related osteonecrosis of the jaw (BRONJ)
appears to be refractory to conventional treatment approaches. We offer our experiences
and treatment strategies regarding the successful resolution of BRONJ.
Materials and methods: Thirty sites of BRONJ in 27 patients were clinicopathologically
proven. The mandible was more commonly affected than the maxilla (67% versus 33%). The
appearance of 23 (77%) BRONJ sites was preceded by a tooth extraction, dental infection,
or oral trauma, and the remaining sites occurred spontaneously. There was a female predilec-
tion with a ratio of 3.5:1, and 22 (81%) patients were oral bisphosphonate (BPh) users. The
treatment strategies included: (1) nonsurgical treatment using antimicrobial rinses; (2)
removal of necrotic bone followed by insertion of Gelfoam impregnated with tetracycline;
or (3) filling with alloplastic bone substitute plus tetracycline as the procedure of guided bone
regeneration (GBR); and (4) radical resection of all necrotic bone and immediate reconstruc-
tion.
Results: In 25 (93%) patients with 27 (90%) sites, BRONJ was successfully treated. The three
treatment failures were all in two intravenous BPh users. There was no significant depen-
dence of the treatment results on the severity of BRONJ. However, there was a significant
dependence of the treatment result on the route of BPh administration.gy and Family Dentistry Section, Department of Dentistry, Kaohsiung Chang Gung Memorial Hospital,
aohsiung, Taiwan.
cgmh.org.tw, lulujasmine@gmail.com (S.-Y. Lu).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
3.004
186 S.-Y. Lu et alConclusion: Our study demonstrates a high success rate of conservative and surgical treat-
ment of BRONJ. This is the first reported use of GBR to successfully treat oral BPh-related os-
teonecrosis of the jaw. Irrigation with antimicrobial rinses may result in pain reduction, and
regression or even resolution of BRONJ.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Bisphosphonates (BPhs) have been widely prescribed for
the treatment of diseases characterized by intense bone
resorption such as osteoporosis, Paget’s disease of bone,
hypercalcemia of malignancy, multiple myeloma, and car-
cinoma metastasizing to the skeleton. These drugs have
also been associated with a serious side effect, osteonec-
rosis of the jaw.1,2 Because of a greater awareness of BPh-
related osteonecrosis of the jaw (BRONJ) among physicians,
oncologists, and the dental community, the number of re-
ported cases has increased dramatically since the first
report by Marx in 2003.1e3 Patients with skeletal events
associated with metastatic neoplasms or multiple myeloma
who are receiving intravenous (i.v.) BPh have represented
94% of published cases to date.1
It is important to make a distinction between osteo-
necrosis of the jaw induced by oral BPh versus that induced
by i.v. BPh. Oral BPh-induced osteonecrosis appears to be
less frequent, less severe, more responsive to discontinu-
ation of the drug, and curable with surgical debridement.1
However, the risk and severity of BRONJ are likely to in-
crease with a longer duration of oral BPh therapy (i.e., 3
years or more).4
The pathogenesis of BRONJ can be summarized as fol-
lows: BPhs are powerful inhibitors of osteoclastic activity
and promoters of osteoclast apoptosis. Therefore, they
cause decreased bone resorption and bone formation
through the uncoupling of the functional osteoclast/oste-
oblast balance. The antiangiogenic properties of BPhs cause
reduced osseous vascularity, which contributes to impaired
physiologic remodeling and wound healing in the jawbone.
Furthermore, BPhs have a strong affinity for hydroxyapatite
crystals and are incorporated into the skeleton, without
degradation, persisting in the skeleton as active drugs. The
estimated half-life for alendronate is up to 12 years, and
for zoledronate up to 10 years.1,4e7 As a result, the bone
turnover is oversuppressed, and self-healing capacity is
reduced.
Based on current understandings in the field, BRONJ
appears to be limited to the jaws. This is conceivable
because the jawbones are sites of high physiologic bone
turnover and increased circulation, which lead to high
concentrations of BPhs within the bone. Furthermore, there
is potential communication between the oral flora and the
bone through the teeth and periodontal tissues, and the
thin mucosa covering the jawbones. It has been observed
that lesions are more common in the mandible than the
maxilla (a 2:1 ratio), and 60% of the cases are preceded by a
dental surgical procedure.1,4 However, a number of eden-
tulous or dentate patients have developed BRONJspontaneously.4,8 The phenomenon of spontaneous
appearance of BRONJ may be explained by the fact that,
once “metabolically damaged” by the BPh therapy, the
jawbones remain susceptible even to minor causative fac-
tors such as injuries of the mucosa, occlusion, or prosthetic
trauma.7 In addition to local and drug-related risk factors, a
variety of systemic risk factors such as advanced age, ra-
diation, smoking, alcohol abuse, diabetes, glucocorticoid
treatment, and immunosuppressive chemotherapy must
also be considered as possible cofactors.1,4
BRONJ remains a difficult condition to treat. There are
few reported studies of the successful treatment of
BRONJ, and the most effective management of BRONJ re-
mains controversial. Numerous retrospective studies have
reported that pharmacologic and surgical therapies are not
able to cure this complication. There are no data that
favor one therapeutic choice over another, and surgery
appears to worsen the course of the disease.7,9 We
therefore present a retrospective case series study of
BRONJ in southern Taiwan treated with varied treatment
strategies.
Materials and methods
Twenty-seven patients (21 females and 6 males, aged from
59 years to 99 years, with a mean age 76 years) with a total
of 30 sites of BRONJ (20 in the mandible and 10 in the
maxilla) diagnosed at the Oral Pathology and Family
Dentistry Department of Kaohsiung Chang Gung Memorial
Hospital during the study period were all included in a
retrospective case series analysis. The observation period
for the study started in February 2008 and ended in
February 2012. Operations were performed from February
2008 to December 2010. Median follow-up was 82 weeks
(ranging from 48 weeks to 126 weeks). Patients’ charac-
teristics and treatment results are listed in Tables 1 and 2.
Depending on the severity of the BRONJ, every site was
grouped according to the clinical staging system published
by Wilde et al (Table 3).10 All patients were informed that
the therapy should be regarded as an individual attempt at
healing, and consented. The following treatment proce-
dure was applied in all patients with consideration of the
stage and severity of BRONJ and the patient’s general
health status: (1) conservative treatment with a daily
antimicrobial rinse, using 0.1% or 0.2% chlorhexidine, was
started after the first appointment for all patients. Pa-
tients and their families were taught how to perform the
oral irrigation by themselves if patients could not visit the
clinic every week. In patients with symptoms of acute
infection, oral antibiotics (amoxicillin or clindamycin in
cases of allergy to beta-lactam antibiotics) were
Table 1 Patient characteristics.
Case Sex/age Primary disease BPh BRONJ Treatment Period with healed
BRONJ in weeksLocation Stage Cause Strategy Result
1 F/76 Bca A 14e15 II SE Irrig þ 16
2 M/85 Lca/Op A 27e28 II Ex Irrig þ 16
3 M/80 Pca/Cca/DM Z 37e38 IV Ex Irrig/Curre HBO þ 68
4 M/72 Pca ZþB 43e46 II Ex Irrig þ 32
5 M/71 MM Z 37 II Ex Irrig  78 a
45e46 II SE Irrig  54 a
6 F/63 Op A 34e36 III Ex Irrig/Curre þ 48
7 M/61 Pca Z 45 III Ex Irrig/Curre  24 a
8 F/74 Op A 12e22 III PR Ext/De þ 8
9 F/89 Op A 16e17 III PR Ext/De þ 8
10 F/87 Op A 21e23 III PR Ext/De þ 8
11 F/73 Op A 12e13 III PR Ext/De þ 12
12 M/76 Op A 45e47 III PR Ext/De þ 12
13 F/80 Op A 47e48 III Ex Curre/De þ 12
14 F/59 Op/Bca A 17 II PR Ext/De þ 8
15 F/83 Op A 33 II PR Ext/De þ 8
46 III Ext/De þ 12
14e15 III GBR þ 12
16 F/83 Op A 48 III Ex GBR þ 6
17 F/74 Op A 33e34 II Ex GBR þ 8
18 F/81 Op/DM A 32e33 III Ex HBO /GBR þ 8
19 F/99 Op A 38 III Ex GBR þ 6
20 F/67 Op AþB 23 II Ex GBR þ 6
21 F/77 Op/DM A 43e44 II Ex GBR þ 6
22 F/83 Op A 14e15 III PR GBR þ 8
23 F74 Op A 48 II PR GBR þ 8
24 F/63 Op A 34e35 III Ex GBR þ 16
25 F/59 Op A 46 II Ex GBR þ 12
26 F/81 Op/DM A 44e46 IV Ex Res/Rec þ 6
27 F/83 Op A 45e47 IV Ex Res/Rec þ 8
The FDI tooth-numbering system is used for description of the location of BRONJ. The staging system of BRONJ according to Wilde et al.
was used (Table 3).10
AZ alendronate (Fosamax); BZ ibandronate (Boniva); BcaZ breast cancer; BPhZ bisphosphonate; BRONJZ bisphosphonate-related
osteonecrosis of the jaws; Cca Z colon cancer; Curre Z Currettage; De Z debridement and filled with Gelfoam impregnated with
tetracycline; DM Z diabetes mellitus; Ex Z tooth extraction; F Z female; GBR Z guided bone regeneration with alloplastic bone
substitute plus tetracycline; HBO Z hyperbaric oxygen therapy; Irrig Z irrigation; Lca Z lung cancer; M Z male; MM Z multiple
myeloma; Op Z osteoporosis; Pca Z prostate cancer; PR Z residual root and/or periodontal disease; Rec Z reconstruction;
Res Z resection; SE Z spontaneous exfoliation of tooth; Z Z zoledronate (Zometa); þ Z successful treatment;  Z unsuccessful
treatment.
a Downstaging of BRONJ and reducing acute symptoms.
Successful treatment of BRONJ 187administered immediately for 1e2 weeks. The duration of
the conservative therapy was not limited to a defined
outcome, but instead depended on patient compliance or
a suitable timing for surgery if the patient’s general health
allowed; (2) all patients receiving surgical therapy (Stage II
or Stage III BRONJ) underwent curettage and removal of
necrotic bone and loose teeth. After that, each had further
treatment consisting of either Gelfoam impregnated with
tetracycline when primary closure was not available, or
alloplastic bone substitute [micro macroporous biphasic
calcium phosphate (MBCP)] with tetracycline and covered
with an absorbable collagen membrane as a guided bone
regeneration (GBR) procedure when a hermetic wound
closure could be achieved; (3) for Stage IV BRONJ with
pathologic mandibular fractures, surgery consisted ofradical segmental resection and immediate reconstruction
with a Synthes AO Compact 2.0 mandible plate (Synthes
Co., Swiss) followed by primary wound closure with su-
tures; (4) removal of sutures was not performed earlier
than 14 days after the operation; and (5) after surgery, the
patients were seen daily for the first week, weekly for the
first month, once a month in the following 6 months, and
every 3 months thereafter. The patients were always
examined with regard to the possible clinical symptoms
and signs of BRONJ: (a) pain, (b) swelling, (c) nonhealing
mucosal ulcer, (d) recurrent abscess or fistula formation
with connection to the bone, (e) exposed necrotic bone,
and/or (f) changes in the periodontal health of adjacent
teeth such as widening of the periodontal ligament space
and osteosclerotic lamina dura or loose teeth.
Table 2 Treatment results associated with the stage of bisphosphonate (BPh)-related osteonecrosis of the jaws and patient
characteristics.
BRONJ (%) Stage II* Stage III* Stage IV*
Oral BPh 24 sites/22 cases (80/81) 8 (þ) sites/6 cases 14 (þ) sites/14 cases 2 (þ) sites/2 cases
Intravenous BPhy 5 sites/4 cases (17/15) 1 (þ) site/1 case 1 () site/1 casey 1 (þ) site/1 case
2 () sites/1 casey
Oral and intravenous BPh 1 site/1 case (3/4) 1 (þ) site/1 case 0 0
Successful treatment 27 sites/25 cases (90/93) 10 (þ) sites/8 cases 14 (þ) sites/14 cases 3 (þ) sites/3 cases
Unsuccessful treatment 3 sites/2 case (10/7) 2 () sites/1 case* 1 () site/1 case* 0
Total sites/cases 30 sites/27 cases 12 sites/9 cases 15 sites/15 cases 3 sites/3 cases
*Not significant: P Z 0.574; y Significant: P Z 0.028.
BRONJ Z bisphosphonate-related osteonecrosis of the jaws; þ Z successful treatment; e Z unsuccessful treatment.
188 S.-Y. Lu et alTreatment success was defined according to the
following criteria: complete healing of BRONJ with no
exposed necrotic bone, no residual mucosal ulcer, no fis-
tulas, and no swelling or pain. Treatment was defined as
unsuccessful if there were sites without complete healing,
as defined above, or if recurrence of clinical signs of BRONJ
were seen at any time during the follow-up period. We also
defined the “period with healed BRONJ” as the period of
time after treatment until final monitoring of the patient
during the observation period with a clinical appearance of
complete healing of BRONJ.
All collected data were analyzed using the computer
package SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). The
Chi-square test was used to analyze the association be-
tween qualitative variables. In all analyses, P < 0.05 was
considered statistically significant. The study was approved
by the Institutional Review Board of Chang Gung Memorial
Hospital.Results
Of the 27 patients (30 sites of BRONJ), BPh therapies (22
oral, 4 i.v., 1 oral plus i.v.) were discontinued by prescribingTable 3 Clinical staging of bisphosphonate (BPh)-related
osteonecrosis of the jaws by Wilde et al.
Stage Clinical symptoms and signs and radiographic
findings in BPh therapeutic patients
0 No exposed/necrotic bone
I Asymptomatic exposed/necrotic bone, no
infection
II Exposed/necrotic bone with pain and infection,
single intraoral fistula, loose tooth, widening
periodontal ligament space
III Exposed/necrotic bone with pain, infection,
swelling, abscess or multiple intraoral fistulas, and
obvious osteolysis in radiography
IV Exposed/necrotic bone with pain, infection,
swelling, abscess, pathologic fracture, naso-oral
fistula, extraoral fistula or osteolysis extending to
the inferior border of mandible
Note: From Reference 10. Reprinted with permission.physicians after the diagnosis of BRONJ. All patients (21
with osteoporosis and 6 with skeletal events associated
with metastatic neoplasms) were monitored, and some
were prescribed an alternative therapy to control their
osteoporosis. A total of 22 patients (24 sites of BRONJ) were
treated surgically, and five patients (6 sites) were treated
nonsurgically. Twenty-five (93%) patients and 27 (90%) sites
were treated successfully with a mean “period with healed
BRONJ” of 14 weeks (range 6e68 weeks). The three treat-
ment failures occurred in two i.v. BPh users. There was a
significant dependence of the treatment result on the
administration of BPh therapy (P Z 0.028). Of the 30 sites,
12 were classified as Stage II BRONJ, 15 as Stage III BRONJ,
and 3 as Stage IV BRONJ (see Tables 1 and 2).
The three treatment failures were one in Stage III and two
in Stage II BRONJ. The statistical analysis showed no signifi-
cant dependence of treatment result on the severity of the
BRONJ (PZ 0.574). Two of the three treatment failure sites
were located in a patient whose mandible was involved by
myeloma. It was difficult to define the real extent of the
BRONJ in the left mandible during curettage, and a new site
of spontaneous BRONJ developed in the right mandible
during the follow-up period. The involvement of the
mandible by the neoplastic process was recognized as one of
the reasons for treatment failure. In the case of our 2-year
observation, conservative treatment was found to reduce
the symptoms and lead to the downstaging of BRONJ.
Four patients with carcinoma metastasizing to the
skeleton declined any aggressive surgical treatment, but
successful treatment of BRONJ was achieved after conser-
vative treatment. One of these four patients (Case 3) is
notable. Case 3 was diagnosed with Stage II BRONJ in June
2009 and experienced progressive worsening of BRONJ to
Stage IV (appearance of an extraoral sinus tract, a large
necrotic bone exposure, and adjacent pathologic fracture
of the left mandible) after hyperbaric oxygen therapy
(HBO) was provided in July 2009 to October 2009. He
refused the suggestion of radical resection due to poor
general health. However, he and his family complied with
the recommended treatment regimen, consisting of a daily
rinse, weekly irrigation, and twice conservative curettage
of draining sinus during the follow-up period. The sinus
tract closed in May 2010. Finally, he agreed that a large and
free sequestrum be removed under local anesthesia in July
2010. Successful treatment of BRONJ with complete re-
Figure 1 An example of successful resolution of Stage IV bisphosphonate-related osteonecrosis of the jaw (BRONJ) by conser-
vative treatment consisting of chlorhexidine daily rinses and oral irrigation in Case 3. (A) Panoramic radiograph on initial diagnosis
of Stage II BRONJ with an unhealed extraction wound of tooth 37 in June 2009. (BeD) Progressive worsening of BRONJ to Stage IV
with appearance of an extraoral sinus tract, a large necrotic bone exposure, and adjacent pathologic fracture of the left mandible
after hyperbaric oxygen therapy during July 2009 to October 2009. (E, G) Panoramic radiograph showing progressive improvement
with partial bone regeneration of the mandibular border and sequestration after regular irrigation and twice conservative
curettage of the draining sinus during November 2009 to June 2010. (F, H) A large necrotic bone specimen was easily removed on
July 2010, and a large deep defect remained. (I, J) Continuing antimicrobial rinsing resulted in complete healing with re-
epithelialization, partial bone regeneration, and a thickening mandibular border found in December 2010.
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Successful treatment of BRONJ 191epithelialization, partial bone regeneration, and thickening
mandibular border was achieved by weekly irrigation in
December 2010 (Fig. 1).
In 21 sites of BRONJ, 14 Stage III and 7 Stage II, were
successfully treated by the removal of loose teeth (10 sites)
and necrotic bone (21 sites). In 11 sites, GBR included MBCP
plus tetracycline followed by coverage with an absorbable
collagen membrane (Fig. 2), and in 10 sites included
insertion of Gelfoam impregnated with tetracycline. All
wounds were sutured. The sufficient wound closure after
GBR procedure provided safe coverage for the bone graft
and reduced the risk of recurrent infection of bone.
In only two of 30 sites, segmental resection of the
mandible and immediate reconstruction plate were per-
formed (Fig. 3), but plate exposure and plate fracture in
Case 27 was observed 2 months after the operation.
Therefore, the Synthes AO Compact 2.0 mandible plate
(Synthes Co., Swiss) was removed, and severe malocclu-
sion had developed due to deviation of the remaining
mandible. Despite this, there was no recurrence of BRONJ.
Except for Case 27, all patients lived a life without any
masticatory discomfort during the observation period of
12e36 months.Discussion
In this retrospective case series, 22 patients (24 sites of
BRONJ) were treated surgically and 21 patients (23 sites of
BRONJ) were treated successfully. Of the five patients
(6 sites) treated nonsurgically, four patients (4 sites) were
treated successfully. In general, most of the sites treated
nonsurgically were Stage II BRONJ, whereas most of the
sites treated surgically were Stage III or higher. Progressive
improvement was seen in five patients with conservative
treatment. The conservative treatment can reduce acute
symptoms and lead to regression or even resolution of
BRONJ.11e15
Of the 27 patients, 22 (81%) had been oral BPh users for
2e9 years, four (15%) were i.v. BPh users, and one oral BPh
user was also on i.v. ibandronate therapy. There were four
patients with diabetes. A number of studies have provided
compelling evidence that the development of BRONJ under
oral BPh medication is far less likely.1e3 However, the real
incidence of BRONJ among the oral BPh population might be
higher because the effects of oral BPh often lag behind
those of i.v. BPh. It has been reported that 6e12 months of
i.v. BPh therapy are equivalent to 3e5 years of oral BPh.3,4
Over 80% of our patients in this investigation were taking
oral BPh therapy; furthermore, the longer duration of
therapy and systemic risk factors such as diabetes, uremia,Figure 2 Examples of guided bone regeneration (GBR) with allo
Case 12 (EeH). (A) Clinical photograph of Case 11 on initial diagno
(BRONJ) with a mucosal defect connection to the necrotic bone. (B
of teeth 33 and 34. (C) Postoperative intraoral image 8 weeks lat
postoperatively showing bone regeneration. (E) Clinical photograph
abscess and a fistulous connection to the necrotic bone probed b
unhealed extraction wound of teeth 32e33 with obvious osteolysis
months later with no signs of BRONJ. (D) Periapical radiograph 4
tooth 31 and partial bone regeneration over teeth 32 and 33.systemic cancer, and advanced age were also present and
likely contributed to the risk.
Newer dose forms of BPh, including ibandronate
(Boniva), used once monthly (oral) or quarterly (i.v.), and
zoledronic acid (Aclasta), used once yearly (i.v.), have been
shown to increase patient compliance and improve thera-
peutic outcomes in the treatment and prevention of oste-
oporosis.16 Their use is expected to increase over time. It is
notable that Boniva is one of the most commonly prescribed
drugs, with isolated reports of the development of BRONJ in
osteoporosis patients, and it remains to be observed
whether cases of BRONJ will increase.16,17
In the study, all patients obtained permission from their
prescribing physician to interrupt BPh therapy once BRONJ
was diagnosed. Many investigators describe a positive ef-
fect of a holiday from oral BPh; however, considering the
very long half-life of BPh and high potency of i.v. BPh, a
drug holiday from BPh prior to or during any treatment may
not provide a prompt positive effect.1,4,15
All physicians and dentists should be aware of the ad-
vantages and disadvantages of BPh.16,17 Despite the risk of
BRONJ, BPh therapy can prevent progression of skeletal
morbidity and reduce excruciating bone pain in patients
with osteolytic forms of cancer. The benefits of oral and i.v.
BPh in the management of osteoporosis, to prevent fracture
and its associated morbidity and mortality, is also signifi-
cant and should be considered by physicians and patients
when deciding whether or not to discontinue the use of BPh
in patients with BRONJ. The true benefit of discontinuing
BPh use in the management of BRONJ requires further
investigation.
Regular long-term follow-up of BRONJ is essential because
there can be a relapse or an occurrence of new BRONJ in a
different site. Typical signs and symptoms are pain, soft tis-
sue swelling and infection, exposed necrotic bone, recurrent
abscesses, and draining fistula. However, some atypical signs
and symptoms that may occur prior to the appearance of
clinically evident BRONJ include nonhealing mucosal ulcers,
changes in the health of periodontal tissues, loose teeth, and
unexplained soft tissue infection or pinpoint mucosal perfo-
ration with connection to the bone.4,18,19
It is worth noting that the clinically visible changes and
radiographic images of BRONJ usually do not show the real
extent and severity.1,4,15 Therefore, the early stages of
BRONJ may not be detectable as radiographic changes on
panoramic and periapical films. Late radiographic changes
may mimic classic periapical inflammatory lesions or oste-
omyelitis. Other radiographic findings include nonhealing
extraction sites, widening of the periodontal ligament
space, and an osteosclerotic lamina dura. In cases of
extensive bone involvement, areas of mottled bone similarplastic bone substitute plus tetracycline in Case 11 (AeD) and
sis of Stage II bisphosphonate-related osteonecrosis of the jaw
) Periapical radiograph showing an unhealed extraction wound
er with no signs of BRONJ. (D) Periapical radiograph 4 months
of Case 12 on initial diagnosis of Stage III BRONJ with a swelling
y a gutta percha point. (F) Periapical radiograph showing an
extending to tooth 31. (G) A postoperative intraoral image 2
months postoperatively showing a healed extraction socket of
192 S.-Y. Lu et alto that of diffuse osteomyelitis become evident.4 In cancer
patients, some of these changes may raise the suspicion of
myeloma or metastatic bone lesion.4 Biopsy in some cases
may be indicated to differentiate it from neoplasticFigure 3 An example of segmental resection of the mandible in C
bisphosphonate-related osteonecrosis of the jaw (BRONJ) with an e
the necrotic bone. (C, D) Cone-beam computed tomography show
osteolysis of the inferior border (C; panoramic reconstructed view
radiograph on initial diagnosis of BRONJ with obvious osteolysis of
operatively showing the bone defect with a reconstruction plate. (G
(H) Intraoral image 2 months postoperatively with no sign of BRONosteolysis; however, a biopsy can further contribute to
bone damage.
Three-dimensional radiologic imaging using cone-beam
computed tomography (CT) or multislice CT isase 18. (A, B) Clinical photograph on initial diagnosis of Stage IV
xtraoral sinus tract and intraoral fluctuant mass connection to
ing pathologic fracture of the right mandible with extensive
) and buccal and lingual plates (D; axial view). (E) Panoramic
the right mandible. (F) Panoramic radiograph 6 months post-
) Extraoral image showing a healed scar of the extraoral fistula.
J.
Successful treatment of BRONJ 193recommended prior to any radical surgical
procedure.13,18e21 Some emerging evidence shows that the
combined use of 99m-Tc sestamibi scintigraphy and fluo-
rodeoxyglucose positron-emission tomography (FDG-PET)/
CT scanning may be helpful in the clinical diagnosis of
BRONJ, thereby avoiding the risks of a surgical biopsy.22
The role of surgery in the management of BRONJ remains
controversial. Because BPh is incorporated into the entire
skeleton, it is difficult to determine the extent of affected
bone when undertaking a surgical approach. Current re-
ports recommend the combination of meticulous debride-
ment and sequestrectomy. Aggressive surgery is considered
a treatment of “the last resort” to manage only the most
severe cases.9,15,23,24 In this study, patients with symp-
tomatic BRONJ can benefit from varied conservative and
surgical treatments. The key points in achieving successful
surgical treatment are: (1) to determine the resection
margin by the clinical appearance of bleeding and healthy
bone; (2) to prevent recurrent infection of the bone; and
(3) to have sufficient wound closure without tension, if
possible. This is not always easy to achieve because
bleeding and healthy bones are sometimes not obvious, and
the real extent of necrotic bone is often much greater than
that seen clinically or radiologically. Therefore, a high de-
gree of experience is needed, especially in cases with
jawbones involved by metastatic lesions, myeloma, or
advanced bone sclerosis.12e15,25,26
This is the first report of a GBR procedure used to suc-
cessfully treat osteonecrosis of the jaw induced by oral
BPh. The successful treatment of peri-implantitis by means
of GBR with alloplastic bone substitute plus tetracycline
powder has been described in the literature.27 The bone-
inducing ability of alloplasts can provide some necessary
bone augmentation. Apart from the broad-spectrum anti-
microbial activity, tetracyclines exert many non-antibiotic
effects such as anticollagenase activity, inhibition of con-
nective tissue degradation, incorporation into bones to
form a stable calcium complex, and influence over bone
remodeling. Several tetracyclines have been reported as
potential agents to prevent bone loss and maintain near-
normal rates of bone formation.28,29 The remaining bone
defect left after debridement of a BRONJ site could also
benefit from the GBR procedure to avoid dead space and
provide support for the soft tissue.
In sites of Stage IV BRONJ, a large continuity resection
of the mandible would result in damage to the inferior
alveolar nerve, chin numbness, and malocclusion. There-
fore, an implanted reconstruction plate that is strong
enough and has sufficient wound closure is important for
prevention of plate fracture, plate exposure, and screw
loosening.15 Some reports have claimed that early results
of HBO therapy in the treatment of BRONJ are encouraging
for its potential to augment bone turnover by way of the
signal effects on osteoclasts.30 However, two of 27 pa-
tients (Cases 3 and 18) showed no benefit from HBO, and
its use even led to the upstaging of BRONJ. Therefore, the
therapeutic effect of HBO in BRONJ was limited in our
investigation.
This retrospective case series demonstrates a high suc-
cess rate of conservative and surgical treatment of BRONJ,
with an overall treatment success of 93%. Conservative
treatment consisting of irrigation with antimicrobial rinsesand additional antibiotics in phases of acute infection can
be a therapeutic option for the control of BRONJ symptoms,
especially if the patient’s general health prohibits surgery.
This is the first reported use of GBR to successfully treat
BRONJ. Further investigations with larger numbers of pa-
tients in controlled prospective clinical trials are advised,
prior to recommending surgery with GBR to treat BRONJ.
Despite the positive results of this study, the treatment of
BRONJ remains challenging, and prevention through
avoidance of dental extractions and other triggers is the
preferred strategy.
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